Anti-TNF re-induction may be an effective and less costly strategy to manage secondary loss of response to therapy than dose interval shortening in patients with Crohn’s disease. A retrospective study of 423 Victorian patients with Crohn’s disease found 19% developed secondary loss of response to either infliximab or adalimumab. Just over a third of patients ...
Short bursts of anti-TNFs effective at rebooting response to therapy
By Mardi Chapman
3 Nov 2017